The shelf filing itself is not an immediate dilutive event. Monitor subsequent prospectus supplements and ATM sales disclosures for actual share issuance. The concurrent 10-Q shows adequate cash runway into 2028, reducing the likelihood of an urgent capital raise.
Drugs in focus
IMNM drug pipeline →varegacestat
▲ Bullish Named in this S-3ASR- Impact
- Phase
- Filed/PDUFA
- Time to market
- FDA PDUFA target action date is April 28, 2027. EMA review is also underway following MAA validation in October 2026. If approved, varegacestat could launch in the US in the second half of 2027.
- Next catalyst
- PDUFA date · Apr 28, 2027 162d
What to watchThe single most important catalyst is the FDA PDUFA decision on April 28, 2027. Approval would make varegacestat the second FDA-approved therapy for desmoid tumors and unlock a meaningful commercial opportunity, while a Complete Response Letter would severely pressure the stock given the company's pre-revenue status and reliance on this asset. Watch for EMA review progress and Q3 earnings on November 16 for pipeline updates and cash runway details.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $18.65entry
- T+1 · 6d ago +2.25%α +0.93% · $19.07
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Immunome filed an automatic shelf registration (S-3ASR) as a well-known seasoned issuer, including an ATM sales agreement prospectus for up to $134.1 million of common stock through TD Cowen. The company had $461.6 million in cash and securities as of September 30, 2026, with a cash runway into 2028, suggesting this is an opportunistic shelf filing rather than a distress-driven capital raise.
Key Facts
- S-3ASR filed as a well-known seasoned issuer with no limit on aggregate securities offered under the base prospectus
- ATM sales agreement prospectus for up to $134.1 million of common stock through TD Cowen
- Prior ATM agreement had $200M authorization; $65.9M in gross proceeds raised from 6,655,587 shares sold under prior ATM
- Cash and securities totaled $461.6M as of September 30, 2026, down from $582.7M at Q1 end
- Cash runway projected into 2028 per the 10-Q filed concurrently
- PDUFA target action date of April 28, 2027 for varegacestat (desmoid tumors)
- 113,647,456 shares outstanding as of September 30, 2026
Financial Impact
Up to $134.1 million in potential gross proceeds from ATM sales; no immediate dilution as no shares are sold at filing
Risk Factors
- Potential dilution from future ATM sales of up to $134.1 million
- Cash burn rate: cash and securities declined $121.1M from Q1 to Q3 2026
- Accumulated deficit of $940.9M as of September 30, 2026
- Short interest of 17.3M shares (~14.6% of estimated shares outstanding)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3ASR Filing (Primary) | 0001193125-26-453803 |
| Document: d137036dex47.htm | 0001193125-26-453803 |
Track record
20 reports on IMNM
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +26.53% at T+60 after the May 28, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $18.39 Now $17.61 −4.24% settles Feb 12
- Nov 9, 20267d ago S-3ASR Neutral 3/10 Viewing Entry $18.65 Now $17.61 −5.58% settles Feb 8
- Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $18.65 Now $17.61 +5.58% settles Feb 8
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $18.21 Now $17.61 −3.29% settles Jan 28
- Oct 16, 20264w ago ANALYST-UPGRADE Bullish 4/10 Entry $16.47 Now $17.61 +6.92% settles Jan 13
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $21.17 Now $17.61 −16.82% settles Dec 30
- Oct 1, 20266w ago ANALYST-UPGRADE Bearish 4/10 Entry $20.89 Now $17.61 +15.70% settles Dec 28
- Sep 21, 20268w ago ANALYST-UPGRADE Bullish 4/10 Entry $25.07 Now $17.61 −29.76% settles Dec 15
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $26.42 to $18.71 Now $17.61 −33.35% ▼ −29.18% −23.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers